Pharmacological + non-pharmacological treatment | IV + | – | – | D | 86.94 (5.82) |
Treatment tailored according to risk factors, severity of hip OA, and patient expectations | III + | – | – | C | 92.19 (3.39) |
Education | Ib + | – | – | A | 71.75 (6.42) |
Exercise | – | – | – | N/A | 71.58 (6.30) |
Insole/stick | IV + | – | – | D | 61.72 (6.91) |
Weight loss | III + | – | – | D | 68.28 (5.79) |
Paracetamol | – | Ia −, III ± (GI) | Cost saving | N/A | 79.19 (3.82) |
NSAIDs | Ia + | Ia +, III+ (GI) | – | A | 79.36 (4.18) |
Coxibs | Ia + (GI protection) | Ia ± (CV) | Higher GI risk population | A | 79.44 (3.51) |
Misoprostol | Ia + (GI protection) | Ia + (diarrhoea) | Higher GI risk population | A | 46.06 (5.62) |
H2 Blockers (double dose) | Ia + (GI protection) | – | High GI risk population | A | 31.28 (6.81) |
PPIs | Ia + (GI protection) | – | – | A | 73.86 (3.97) |
Opioids | Ib + | Ia + (any, GI, CNS) | – | A | 43.97 (4.36) |
Glucosamine | – | – | – | N/A | 37.06 (5.03) |
Chondroitin | Ib + | – | – | A | 34.44 (4.76) |
Diacerhein | Ib ± | Ib + (dyspepsia) | Short term | Inconclusive | 27.83 (5.38) |
Avocado soybean unsaponifiable | Ib − | – | – | Not recommended | 31.72 (4.79) |
Hyaluronic acid | III + | – | – | C | 22.83 (4.17) |
Intra-articular steroid | Ib − | – | – | Not recommended | 41.47 (5.74) |
Osteotomy | III + | – | – | C | 59.64 (5.19) |
THR | III + | – | Women with younger age | C | 86.86 (2.42) |